immuno-oncology
Vaxon Biotech completes enrollment for mid-stage trial of lung cancer vaccine
March 16, 2016Research and Development, Sales and Marketing NSCLC, immuno-oncology, vaxon biotech
Vaxon Biotech on Wednesday said it has completed the enrollments for mid-stage trials of its vaccine to treat non-small-cell lung …
Japan’s Ono Pharma focusing on building immuno-oncology portfolio with Opdivo
March 7, 2016Sales and Marketing Bristol-Myers Sqibb, Ono Pharma, immuno-oncology, opdivo
Japan’s Ono Pharmaceutical has said it is focused on building on its immuno-oncology portfolio following the success of its PD-1 …
AbbVie and MD Anderson in cancer research partnership
January 25, 2016Research and Development, Sales and Marketing AbbVie, MD Anderson Cancer Centre, immuno-oncology
AbbVie has announced a new partnership with The University of Texas MD Anderson Cancer Centre, using its immunotherapy platform to …
MSD to acquire Scottish firm IOmet Pharma
January 12, 2016Research and Development, Sales and Marketing IOMet Pharma, MSD, Merck, Scotland, acquisitions, immuno-oncology, mergers, oncology
US pharma company MSD is to buy Edinburgh based IOMet Pharma to expand its existing R&D programme, exploring the development …
Sanofi seals double oncology research deals
January 11, 2016Research and Development, Sales and Marketing Sanofi, Warp Drive Bio, antibodies, collaboration, immuno-oncology, research
Sanofi has signed two separate research agreements for €1.2 billion, which will give the French firm licensing rights to potential …
Novartis expands immuno-oncology programme
January 11, 2016Research and Development, Sales and Marketing Cancer, Novartis, Surface Oncology, collaboration, immuno-oncology
Novartis has further bolstered its immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology, as it moves …
PsiOxus Therapeutics appoints Dr Paolo Paoletti as chairman of the board
January 7, 2016Manufacturing and Production, Medical Communications, Research and Development Cancer, Dr Paolo Paoletti, GSK, PsiOxus Therapeutics, immuno-oncology, oncology
Immuno-oncology company PsiOxus Therapeutics has appointed Kesios Therapeutics chief executive, and former president of GSK Oncology, Dr Paolo Paoletti, as chairman …
Janssen, Enterome and Kymab in research collaborations
January 7, 2016Research and Development Crohn's, Crohn’s disease, Enterome, Janssen, MD Anderson, alliance, antibodies, collaboration, crohn's disease, immuno-oncology, kymab, research
Several pharma companies have announced new collaborations, to research potential new drugs for Crohn’s disease, and immuno-oncology treatments for cancer. …
Bristol-Myers Squibb in new oncology collaboration
November 25, 2015Research and Development Bristol-Myers Squibb, collaboration, immuno-oncology, investment, venture capital
Bristol-Myers Squibb and European healthcare fund Life Sciences Partners are forming a strategic collaboration to identify breakthrough technologies. The companies …
$350m collaboration deal for BMS and Five Prime Therapeutics
October 15, 2015Research and Development BMS, Bristol-Myers Squibb, R&D, five prime, immuno-oncology, tumours
Bristol-Myers Squibb has signed a collaboration agreement with the US biotech firm Five Prime Therapeutics, for a Colony Stimulating Factor …
Ablynx and Merck begin immuno-oncology collaboration
October 15, 2015Research and Development Ablynx, Merck, immuno-oncology, nanobody, proof of concept
Ablynx has achieved a pre-clinical proof-of-concept with a nanobody construct as part of its immuno-oncology collaboration with Merck – triggering …
FDA grants Opdivo breakthrough status for kidney cancer
September 18, 2015Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma
The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …
Bristol-Myers Squibb makes big pharma deals
September 1, 2015Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis
Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …
Sanofi, Evotec and Apeiron partner on immuno-oncology
August 10, 2015Research and Development, Sales and Marketing Apeiron, Cancer, Evotec, Sanofi, immuno-oncology, immunotherapy, tumours
Sanofi is partnering with biotech companies Evotec and Apeiron to develop new cancer immuno-oncology therapies.The companies say the potential new …
MedImmune and Mirati to partner on lung cancer combo
August 6, 2015Research and Development AstraZeneca, Cancer, MedImmune, Mirati, Mirati Therapeutics, NSCLC, durvalumab, immuno-oncology, immunotherapy, lung cancer, mocetinostat
MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
